Hormone Therapy Options for Endometriosis — A Realistic Guide

Hormonal medical management is the cornerstone of long-term endometriosis care. This page explains the major classes of hormone therapy, what each does, who they suit, and their realistic trade-offs, so you can make informed choices alongside your specialist.

1. Combined oral contraceptive (COC)

The most commonly prescribed first-line. Combination of oestrogen + progestin, suppresses ovulation and reduces cyclical disease activity. Continuous use (skip the placebo week) is often preferred for endometriosis to suppress menstruation entirely. Pros: cheap, well-tolerated, contraception bonus. Cons: thrombosis risk in selected patients, not always sufficient for severe disease.

2. Progestin-only therapy

Norethisterone, dienogest, medroxyprogesterone acetate. Suppresses endometrium and ovulation. Continuous dienogest (Visanne) is well studied for endometriosis pain. Pros: avoids oestrogen, suitable for migraine-with-aura, thrombosis history, smoking over 35. Cons: irregular bleeding, mood effects, weight gain in some patients.

3. Levonorgestrel-releasing intrauterine system (Mirena)

Local progestin release directly to the uterus. Reduces menstrual bleeding by 90% within 6 months. Effective for endometriosis-related dysmenorrhoea, particularly with coexisting adenomyosis. Pros: 5–8 years effect, minimal systemic side effects. Cons: insertion discomfort, irregular bleeding initially, occasional expulsion.

4. GnRH agonists

Goserelin, leuprolide, triptorelin. Induce pseudomenopause by suppressing pituitary FSH/LH. Highly effective for severe pain and pre-surgical disease shrinkage. Pros: powerful suppression. Cons: menopausal side effects (hot flushes, mood, bone loss). Requires “add-back” therapy (low-dose oestrogen + progestin) for use beyond 6 months.

5. GnRH antagonists, the new class

Elagolix, relugolix combinations. Oral, rapid onset, dose-adjustable suppression. Lower-dose options preserve some ovarian function while reducing pain. Pros: oral, flexible dosing, less severe menopausal symptoms at lower doses. Cons: cost, newer (less long-term data), still some hypoestrogenic effects.

6. Selecting the right agent

First-line: COC continuous or Mirena IUS for most patients. Second-line: dienogest if COC contraindicated or insufficient. Third-line: GnRH antagonists or agonists with add-back for refractory pain. Patient factors (contraception need, age, comorbidities, side effect tolerance) drive choice. There is no single best agent, fit matters.

7. Hormonal therapy for fertility-seekers

When pregnancy is being sought, hormonal suppression is paused. Pre-pregnancy disease control reduces post-pregnancy recurrence risk. After delivery and breastfeeding, hormonal management often resumes to prevent recurrence and progression. Decisions integrate fertility timeline with disease severity.

8. Long-term considerations

Hormonal management is often lifelong (until menopause) for moderate-severe disease. Bone density monitoring with prolonged GnRH agonist use. Annual review of side effects, efficacy and quality of life. Switching agents is appropriate if current regimen is not working, there is no single “endometriosis pill”.

Frequently Asked Questions